Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 192

The DOI matches its Crossref record.

Final 5‐year results of Z‐FAST trial: Adjuvant Zoledronic Acid Maintains Bone Mass in Postmenopausal Breast Cancer Patients Receiving Letrozole

Brufsky, Adam M., Harker, W. Graydon, Beck, J. Thaddeus, Bosserman, Linda, Vogel, Charles, Seidler, Christopher, Jin, Lixian, Warsi, Ghulam, Argonza‐Aviles, Eliza, Hohneker, John, Ericson, Solveig G., Perez, Edith A.·2012·Cancer

Abstract

BACKGROUND: Postmenopausal breast cancer (BC) patients receiving adjuvant aromatase inhibitor therapy are at risk of progressive bone loss and fractures. Zoledronic acid inhibits osteoclastic bone resorption, is effective in maintaining bone health, and may therefore be beneficial in this setting. METHODS: Overall, 602 postmenopausal women with early, hormone receptor‐positive BC receiving adjuvant letrozole were randomized (301 each group) to receive upfront or delayed‐start zoledronic acid (4 mg intravenously every 6 months) for 5 years. The primary endpoint was the change in lumbar spine (LS) bone mineral density (BMD) at month 12. Secondary endpoints included changes in LS BMD, total hip BMD, and bone turnover markers at 2, 3, and 5 years; fracture incidence at 3 years; and time to disease recurrence. RESULTS: At month 61, the adjusted mean difference in LS and total hip BMDs between the upfront and delayed groups was 8.9% and 6.7%, respectively (P < .0001, for both). Approximately 25% of delayed patients received zoledronic acid by month 61. Only 1 patient experienced grade 4 renal dysfunction; no confirmed cases of osteonecrosis of the jaw were reported. Fracture rates (upfront, 28 [9.3%]; delayed, 33 [11%]; P = .3803) and Kaplan‐Meier disease recurrence rates (upfront, 9.8 [95% confidence interval (CI), 6.0‐10.3]; delayed, 10.5 [95% CI, 6.6‐14.4]; P = .6283) were similar at month 61. CONCLUSIONS: Upfront zoledronic acid seems to be the preferred treatment strategy versus delayed administration, as it significantly and progressively increases BMD in postmenopausal women with early BC receiving letrozole for 5 years, and long‐term coadministration of letrozole and zoledronic acid is well tolerated. Cancer 2012. © 2011 American Cancer Society.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/cncr.26313

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 192

Metadata

Authors
Brufsky, A. M., Harker, W. G., Beck, J. T., Bosserman, L., Vogel, C., Seidler, C., Jin, L., Warsi, G., Argonza‐Aviles, E., Hohneker, J., Ericson, S. G., & Perez, E. A.
Venue
Cancer
Publisher
Wiley
Published
2011-10-10
Volume
118
Issue
5
Pages
1192-1201
ISSN
  • 0008-543X (ISSN-L)
  • 1097-0142
OpenAlex
W1599466832
Cited by
192
References
0
FWCI
7.45
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Final 5‐year results of Z‐FAST trial: Adjuvant Zoledronic Acid Maintains Bone Mass in Postmenopausal Breast Cancer Patients Receiving Letrozole. https://app.cochat.ai/papers/10.1002/cncr.26313
The paper
Brufsky, A. M., Harker, W. G., Beck, J. T., Bosserman, L., Vogel, C., Seidler, C., Jin, L., Warsi, G., Argonza‐Aviles, E., Hohneker, J., Ericson, S. G., & Perez, E. A. (2012). Final 5‐year results of Z‐FAST trial: Adjuvant Zoledronic Acid Maintains Bone Mass in Postmenopausal Breast Cancer Patients Receiving Letrozole. Cancer. https://doi.org/10.1002/cncr.26313

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.